ICER has published a new evidence report on two drugs for use in lupus nephritis patients. FDA-approved voclosporin and belimumab are of clinical interest given the limited number of treatment options for this disease. The report took into consideration patient outcomes, cost analysis, and benefits to marginalized populations.
“[T]he evidence appears adequate to demonstrate that belimumab and voclosporin provide improved clinical outcomes for patients and may offer important benefits beyond those directly measured in clinical and cost-effectiveness analyses. Substantial uncertainty remains regarding the magnitude of the impact of short-term kidney function improvement on long-term outcomes that matter most to patients, such as progression to renal failure. Relative clinical benefits for Black patients and those from other racial and ethnic groups are not well defined from the existing clinical studies and deserves much greater focus in future research given the high unmet need in these communities.” Read more here.
(Source: ICER, 3/12/21)
